Progeria trial underscores challenge of rare diseases

The mother of a young boy with Progeria has paved the way to the world's first clinical trial into a potential treatment of the disease, which will require recruiting more than half of the 42 known patients in the world. The case underscores both the promise of new genetic research into potential treatments as well as the challenges researchers face in studying rare diseases. Progeria affects only one in every four million to eight million children, most of whom die from a stroke or heart attack by the age of 13.

- here's the article from The Wall Street Journal (sub. req.)

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.